

Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer

Vakaramoko Diaby · Georges Adunlin ·
Simon B. Zeichner · Kiran Avancha ·
Gilberto Lopes · Stefan Gluck · Alberto J. Montero

Published online: 28 August 2014
© Springer Science+Business Media New York 2014

Erratum to: Breast Cancer Res Treat
DOI 10.1007/s10549-014-3042-3

In the original publication, an acknowledgement has been inadvertently omitted. The acknowledgement is given below:

Acknowledgments Vakaramoko Diaby and Georges Adunlin have equal contribution in terms of authorship.

The online version of the original article can be found under doi:[10.1007/s10549-014-3042-3](https://doi.org/10.1007/s10549-014-3042-3).

V. Diaby (✉) · G. Adunlin
Division of Economic, Social and Administrative Pharmacy,
College of Pharmacy and Pharmaceutical Sciences, Florida
A&M University (FAMU), Tallahassee, FL, USA
e-mail: diaby_v@yahoo.fr

S. B. Zeichner
Department of Internal Medicine, Mount Sinai Medical Center,
Miami Beach, FL, USA

K. Avancha
Hartford Healthcare Cancer Institute, Hartford, CT, USA

G. Lopes
HCor Onco, São Paulo, Brazil

G. Lopes
Centro Paulista de Oncologia, São Paulo, Brazil

G. Lopes
Johns Hopkins University, Baltimore, MD, USA

S. Gluck
Division of Hematology/Oncology, Department of Medicine,
Sylvester Comprehensive Cancer Center, Leonard M. Miller
School of Medicine, University of Miami, Coral Gables, FL,
USA

A. J. Montero
Department of Solid Tumor Oncology, Taussig Cancer Center,
Cleveland, OH, USA